US20010036635A1 - Compositions and methods for identifying and targeting cancer cells of alimentary canal origin - Google Patents

Compositions and methods for identifying and targeting cancer cells of alimentary canal origin Download PDF

Info

Publication number
US20010036635A1
US20010036635A1 US09/819,247 US81924701A US2001036635A1 US 20010036635 A1 US20010036635 A1 US 20010036635A1 US 81924701 A US81924701 A US 81924701A US 2001036635 A1 US2001036635 A1 US 2001036635A1
Authority
US
United States
Prior art keywords
sample
stomach
cells
colorectal
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/819,247
Other languages
English (en)
Inventor
Scott Waldman
Jason Park
Stephanie Schulz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US09/819,247 priority Critical patent/US20010036635A1/en
Assigned to THOMAS JEFFERSON UNIVERSITY reassignment THOMAS JEFFERSON UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PARK, JASON, SCHULZ, STEPHANIE, WALDMAN, SCOTT A.
Publication of US20010036635A1 publication Critical patent/US20010036635A1/en
Priority to US10/428,225 priority patent/US20040033520A1/en
Priority to US12/036,875 priority patent/US20080241064A1/en
Priority to US12/554,572 priority patent/US20100015167A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
US09/819,247 2000-03-27 2001-03-27 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin Abandoned US20010036635A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US09/819,247 US20010036635A1 (en) 2000-03-27 2001-03-27 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US10/428,225 US20040033520A1 (en) 2000-03-27 2003-05-02 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US12/036,875 US20080241064A1 (en) 2000-03-27 2008-02-25 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US12/554,572 US20100015167A1 (en) 2000-03-27 2009-09-04 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19222900P 2000-03-27 2000-03-27
US09/819,247 US20010036635A1 (en) 2000-03-27 2001-03-27 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/428,225 Continuation US20040033520A1 (en) 2000-03-27 2003-05-02 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin

Publications (1)

Publication Number Publication Date
US20010036635A1 true US20010036635A1 (en) 2001-11-01

Family

ID=22708782

Family Applications (20)

Application Number Title Priority Date Filing Date
US09/819,248 Abandoned US20010039016A1 (en) 2000-03-27 2001-03-27 Use of expression profiling for identifying molecular markers useful for diagnosis of metastatic cancer
US09/819,254 Abandoned US20010029020A1 (en) 2000-03-27 2001-03-27 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US09/819,249 Expired - Lifetime US6767704B2 (en) 1997-03-12 2001-03-27 Methods of screening and diagnosing esophageal cancer by determining guanylin cyclase C expression
US09/819,247 Abandoned US20010036635A1 (en) 2000-03-27 2001-03-27 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US09/820,215 Abandoned US20020012931A1 (en) 2000-03-27 2001-03-27 High specificity marker detection
US09/819,252 Expired - Fee Related US6844153B2 (en) 2000-03-27 2001-03-27 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US10/428,225 Abandoned US20040033520A1 (en) 2000-03-27 2003-05-02 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US10/611,533 Expired - Fee Related US7745114B2 (en) 2000-03-27 2003-06-30 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US10/866,951 Expired - Lifetime US7854933B2 (en) 1997-03-12 2004-06-14 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US11/036,875 Expired - Fee Related US7479376B2 (en) 2000-03-27 2005-01-14 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US11/058,778 Expired - Fee Related US7485422B2 (en) 2000-03-27 2005-02-16 Detection of CDX2 expression
US12/036,875 Abandoned US20080241064A1 (en) 2000-03-27 2008-02-25 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US12/272,593 Expired - Fee Related US7785817B2 (en) 2000-03-27 2008-11-17 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US12/554,572 Abandoned US20100015167A1 (en) 2000-03-27 2009-09-04 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US12/824,897 Abandoned US20110250228A1 (en) 2000-03-27 2010-06-28 Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
US12/860,835 Abandoned US20110086064A1 (en) 2000-03-27 2010-08-20 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US12/961,373 Expired - Fee Related US8067007B2 (en) 1997-03-12 2010-12-06 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US13/277,612 Expired - Fee Related US8946168B2 (en) 1997-03-12 2011-10-20 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US14/520,962 Expired - Fee Related US9429576B2 (en) 1997-03-12 2014-10-22 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US15/249,291 Abandoned US20170049869A1 (en) 1997-03-12 2016-08-26 Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09/819,248 Abandoned US20010039016A1 (en) 2000-03-27 2001-03-27 Use of expression profiling for identifying molecular markers useful for diagnosis of metastatic cancer
US09/819,254 Abandoned US20010029020A1 (en) 2000-03-27 2001-03-27 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US09/819,249 Expired - Lifetime US6767704B2 (en) 1997-03-12 2001-03-27 Methods of screening and diagnosing esophageal cancer by determining guanylin cyclase C expression

Family Applications After (16)

Application Number Title Priority Date Filing Date
US09/820,215 Abandoned US20020012931A1 (en) 2000-03-27 2001-03-27 High specificity marker detection
US09/819,252 Expired - Fee Related US6844153B2 (en) 2000-03-27 2001-03-27 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US10/428,225 Abandoned US20040033520A1 (en) 2000-03-27 2003-05-02 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US10/611,533 Expired - Fee Related US7745114B2 (en) 2000-03-27 2003-06-30 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US10/866,951 Expired - Lifetime US7854933B2 (en) 1997-03-12 2004-06-14 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US11/036,875 Expired - Fee Related US7479376B2 (en) 2000-03-27 2005-01-14 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US11/058,778 Expired - Fee Related US7485422B2 (en) 2000-03-27 2005-02-16 Detection of CDX2 expression
US12/036,875 Abandoned US20080241064A1 (en) 2000-03-27 2008-02-25 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US12/272,593 Expired - Fee Related US7785817B2 (en) 2000-03-27 2008-11-17 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US12/554,572 Abandoned US20100015167A1 (en) 2000-03-27 2009-09-04 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US12/824,897 Abandoned US20110250228A1 (en) 2000-03-27 2010-06-28 Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin
US12/860,835 Abandoned US20110086064A1 (en) 2000-03-27 2010-08-20 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US12/961,373 Expired - Fee Related US8067007B2 (en) 1997-03-12 2010-12-06 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US13/277,612 Expired - Fee Related US8946168B2 (en) 1997-03-12 2011-10-20 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US14/520,962 Expired - Fee Related US9429576B2 (en) 1997-03-12 2014-10-22 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US15/249,291 Abandoned US20170049869A1 (en) 1997-03-12 2016-08-26 Compositions and Methods for Identifying and Targeting Cancer Cells of Alimentary Canal Origin

Country Status (10)

Country Link
US (20) US20010039016A1 (de)
EP (6) EP1268854A4 (de)
JP (3) JP2003528628A (de)
AT (2) ATE469242T1 (de)
AU (3) AU2001249548A1 (de)
CA (3) CA2404428A1 (de)
DE (2) DE60142228D1 (de)
ES (2) ES2548381T3 (de)
PT (1) PT1272665E (de)
WO (3) WO2001073133A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208045A1 (en) * 2003-09-15 2005-09-22 Wylie Vale Cripto antagonism of activin and TGF-b signaling
US20120226189A1 (en) * 2009-11-13 2012-09-06 Medical Research Council Cell sampling device
EP3444333A1 (de) 2009-10-22 2019-02-20 Thomas Jefferson University Zellbasierte antikrebszusammensetzungen sowie verfahren zur herstellung und verwendung davon

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US6692952B1 (en) * 1999-11-10 2004-02-17 Massachusetts Institute Of Technology Cell analysis and sorting apparatus for manipulation of cells
CA2404428A1 (en) * 2000-03-27 2001-10-04 Thomas Jefferson University High specificity marker detection
AU2001292728A1 (en) * 2000-09-18 2002-03-26 Thomas Jefferson University Compositions and methods for identifying and targeting stomach and esophageal cancer cells
WO2002074979A2 (en) * 2001-03-20 2002-09-26 Ortho-Clinical Diagnostics, Inc. Expression profiles and methods of use
EP2359689B1 (de) 2002-09-27 2015-08-26 The General Hospital Corporation Mikrofluid-Vorrichtung zur Zelltrennung, sowie Verwendung derselben
CA2503621A1 (en) * 2002-11-13 2004-05-27 Genentech, Inc. Methods and compositions for diagnosing dysplasia
DE10259703A1 (de) * 2002-12-19 2004-07-08 Ivonex Gmbh Trennungsverfahren
US7422865B2 (en) * 2003-01-13 2008-09-09 Agilent Technologies, Inc. Method of identifying peptides in a proteomic sample
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
US20040171091A1 (en) * 2003-02-27 2004-09-02 Cell Work, Inc. Standardized evaluation of therapeutic efficacy based on cellular biomarkers
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
WO2004113877A1 (en) * 2003-06-13 2004-12-29 The General Hospital Corporation Microfluidic systems for size based removal of red blood cells and platelets from blood
EP2322547A1 (de) * 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloidzellen-spezifisches Lectin
ATE451475T1 (de) * 2003-07-03 2009-12-15 Gentron Llc Verfahren und systeme zur diagnose von nicht das zentrale nervensystem (zns) betreffenden krankheiten in zns-proben
WO2005040163A1 (en) * 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
JP5095216B2 (ja) 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド アリールイミダゾールおよびその抗癌剤としての使用
WO2005084374A2 (en) * 2004-03-03 2005-09-15 The General Hospital Corporation Magnetic device for isolation of cells and biomolecules in a microfluidic environment
US20050221339A1 (en) * 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
ES2451496T3 (es) 2004-06-25 2014-03-27 Thomas Jefferson University Ligandos de guanilato ciclasa C
WO2006017151A2 (en) * 2004-07-09 2006-02-16 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Identification of makers in esophageal cancer, colon cancer, head and neck cancer and melanoma
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US8535914B2 (en) * 2005-01-21 2013-09-17 Canon Kabushiki Kaisha Probe, probe set and information acquisition method using the same
US20070026417A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026414A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026413A1 (en) * 2005-07-29 2007-02-01 Mehmet Toner Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070196820A1 (en) 2005-04-05 2007-08-23 Ravi Kapur Devices and methods for enrichment and alteration of cells and other particles
US20070026415A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20070026416A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US8921102B2 (en) * 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20090181421A1 (en) * 2005-07-29 2009-07-16 Ravi Kapur Diagnosis of fetal abnormalities using nucleated red blood cells
US20070059680A1 (en) * 2005-09-15 2007-03-15 Ravi Kapur System for cell enrichment
US7939649B2 (en) * 2005-09-06 2011-05-10 Stanford University Polynucleotide encoding luciferase
US20070059781A1 (en) * 2005-09-15 2007-03-15 Ravi Kapur System for size based separation and analysis
US20070059683A1 (en) * 2005-09-15 2007-03-15 Tom Barber Veterinary diagnostic system
US20070059774A1 (en) * 2005-09-15 2007-03-15 Michael Grisham Kits for Prenatal Testing
AU2006330947B2 (en) * 2005-12-22 2012-04-12 Pacific Biosciences Of California, Inc. Polymerases for nucleotide analogue incorporation
AU2006331677A1 (en) * 2005-12-22 2007-07-05 Pacific Biosciences Of California, Inc. Protein engineering strategies to optimize activity of surface attached proteins
US8936926B2 (en) * 2005-12-22 2015-01-20 Pacific Biosciences Of California Active surface coupled polymerases
WO2007081386A2 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use
JP2007215412A (ja) * 2006-02-14 2007-08-30 Shizuoka Prefecture 悪性転移性胃癌の判定方法
US20070207467A1 (en) * 2006-03-01 2007-09-06 Ming Xu Detection of lymph node metastasis from gastric carcinoma
EP2481815B1 (de) 2006-05-11 2016-01-27 Raindance Technologies, Inc. Mikrofluidische Vorrichtungen
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
JP2010527577A (ja) * 2006-05-22 2010-08-19 クリニカル ジェノミクス ピーティーワイ リミテッド 検出方法
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2029779A4 (de) * 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
EP2589668A1 (de) 2006-06-14 2013-05-08 Verinata Health, Inc Analyse seltener Zellen mittels Probentrennung und DNA-Etiketten
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
ES2375453T3 (es) * 2006-09-07 2012-03-01 Universitätsklinikum Hamburg-Eppendorf Método para la detección de células epiteliales cancerosas utilizando citoqueratinas liberadas como marcadores para dichas células.
US8343746B2 (en) * 2006-10-23 2013-01-01 Pacific Biosciences Of California, Inc. Polymerase enzymes and reagents for enhanced nucleic acid sequencing
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
WO2009018446A1 (en) * 2007-08-01 2009-02-05 The Johns Hopkins University Esophageal cancer markers
WO2009070392A1 (en) * 2007-11-27 2009-06-04 Veridex, Llc Automated enumeration and characterization of circulating melanoma cells in blood
CA2760050A1 (en) * 2008-05-13 2009-11-19 Thomas Jefferson University Guanylyl cyclase c qrt-pcr
EP4047367A1 (de) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Verfahren zum nachweis von zielanalyten unter verwendung von tropfenbibliotheken
US20100112575A1 (en) 2008-09-20 2010-05-06 The Board Of Trustees Of The Leland Stanford Junior University Noninvasive Diagnosis of Fetal Aneuploidy by Sequencing
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
CN102333887B (zh) 2009-02-25 2014-04-02 戴格努生命科学公司 用于检测gi癌转移的方法
WO2010111231A1 (en) 2009-03-23 2010-09-30 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2486409A1 (de) 2009-10-09 2012-08-15 Universite De Strasbourg Markiertes nanomaterial auf siliziumbasis mit verbesserten eigenschaften und seine verwendung
CA2774032C (en) 2009-10-23 2019-03-26 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
US20110152993A1 (en) * 2009-11-05 2011-06-23 Sequent Medical Inc. Multiple layer filamentary devices or treatment of vascular defects
EP2517025B1 (de) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Verfahren zur reduzierung des austauschs von molekülen zwischen tröpfchen
US8187979B2 (en) * 2009-12-23 2012-05-29 Varian Semiconductor Equipment Associates, Inc. Workpiece patterning with plasma sheath modulation
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
KR101570404B1 (ko) 2010-03-24 2015-11-20 르 라보레또레 쎄르비에르 결장직장암 및 위창자암의 예방
JP5856048B2 (ja) 2010-04-06 2016-02-09 国立大学法人 鹿児島大学 Ｎ結合型糖鎖を利用した消化器癌の検査方法
EP2622103B2 (de) 2010-09-30 2022-11-16 Bio-Rad Laboratories, Inc. Sandwichassays in tröpfchen
EP3412778A1 (de) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Verfahren zur bildung gemischter tröpfchen
EP3736281A1 (de) 2011-02-18 2020-11-11 Bio-Rad Laboratories, Inc. Zusammensetzungen und verfahren für molekulare etikettierung
EP2686688B1 (de) 2011-03-17 2019-05-08 Cernostics, Inc. Systeme und zusammensetzungen zur diagnose von barrett-ösophagen und verwendungsverfahren dafür
CN102311458A (zh) * 2011-05-31 2012-01-11 江苏省原子医学研究所 一种99mTcO核标记的苯丁酸氮芥类配合物、其制备分离纯化方法及其用途
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
US20140363825A1 (en) * 2011-08-29 2014-12-11 Kyoto University Marker for detecting colorectal cancer or esophageal cancer and method for examining such cancer
JP2013083490A (ja) 2011-10-06 2013-05-09 Kagoshima Univ 消化器癌診断用マーカー、および消化器癌の検査方法
US20130210659A1 (en) 2012-02-10 2013-08-15 Andrew Watson Molecular diagnostic screening assay
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
PL2841575T3 (pl) 2012-04-27 2020-01-31 Millennium Pharmaceuticals, Inc. Cząsteczki przeciwciała anty-gcc i ich zastosowanie do badania podatności na terapię ukierunkowaną na gcc
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
CA2877721A1 (en) 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US9396532B2 (en) * 2012-11-15 2016-07-19 Siemens Healthcare Diagnostics, Inc. Cell feature-based automatic circulating tumor cell detection
WO2014134311A1 (en) * 2013-02-28 2014-09-04 Millennium Pharmaceuticals, Inc. Administration of an anti-gcc antibody-drug conjugate and a dna damaging agent in the treatment of cancer
EP2986762B1 (de) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digitale analyse von analyten
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
JP6946000B2 (ja) 2013-10-04 2021-10-06 アプトース バイオサイエンシーズ， インコーポレイテッド がんの治療用組成物及び方法
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (en) 2013-12-31 2015-07-09 Raindance Technologies, Inc. System and method for detection of rna species
WO2015138889A1 (en) * 2014-03-13 2015-09-17 The Penn State Research Foundation Compositions and methods for diagnosing barrett's esophagus stages
US10539566B2 (en) 2014-12-08 2020-01-21 Berg Llc Use of markers including filamin A in the diagnosis and treatment of prostate cancer
KR20180026659A (ko) 2015-03-18 2018-03-13 더 존스 홉킨스 유니버시티 포타슘 채널 kcnk9를 표적화하는 신규한 모노클로날 항체 억제제
CA2994256A1 (en) 2015-07-31 2017-02-09 The Johns Hopkins University Methods and compositions for treating metabolic reprogramming disorders
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
EP3786640B1 (de) 2015-11-25 2022-08-24 Cernostics, Inc. Verfahren zum nachweis maligner transformation von barrett-esophagus
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
CN106124764B (zh) * 2016-08-12 2018-03-09 上海市嘉定区中心医院 以hoxb9和pbx1作为生物标志物的胃癌检测试剂盒及应用
MX2019011017A (es) 2017-03-14 2020-01-20 Novomics Co Ltd Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii.
US20200376068A1 (en) * 2017-08-18 2020-12-03 Thomas Jefferson University Protection of normal tissue in cancer treatment
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
WO2019041045A1 (en) 2017-09-01 2019-03-07 The Hospital For Sick Children PROFILING AND TREATMENT OF HYPERMUTANT CANCER
CN111417395A (zh) 2017-10-30 2020-07-14 艾普托斯生物科学公司 用于治疗癌症的芳基咪唑
FI128634B (en) * 2019-06-07 2020-09-15 Nokia Solutions & Networks Oy Obtaining information
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3130883A (en) * 1962-03-01 1964-04-28 Lewis J Mackool Hatchet scabbard
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US4022878A (en) 1972-05-15 1977-05-10 Biological Developments, Inc. Methods and compounds for producing specific antibodies
US4526716A (en) 1981-11-20 1985-07-02 The Ohio State University Antigenic modification of polypeptides
US4329281A (en) 1978-06-05 1982-05-11 Hoffmann-La Roche Inc. Hapten compositions
US4264024A (en) * 1978-12-21 1981-04-28 Harris Jr Ellsworth L Smoking pipe sling
US4341763A (en) 1981-03-10 1982-07-27 Smithkline-Rit Methods of vaccinating humans against rotavirus infection
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4584268A (en) 1981-10-13 1986-04-22 Ceriani Roberto Luis Method and compositions for carcinoma diagnosis
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
GB8328918D0 (en) 1983-10-28 1983-11-30 Unilever Plc Alkaline phosphatase
ZA839512B (en) 1983-12-12 1984-08-29 Scripps Clinic Res Synthetic heat-stable enterotoxin polypeptide of escherichia coli and multimers thereof
US4601896A (en) 1984-03-21 1986-07-22 Mark Nugent Pharmaceutical capsule compositions and structures for gastric sensitive materials
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4729893A (en) 1984-12-26 1988-03-08 Robert L. Letcher Enteric encapsulation of ancrod for oral administration
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5160723A (en) 1985-04-19 1992-11-03 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
GB8519457D0 (en) 1985-08-02 1985-09-11 Faulk Ward Page Tumour imaging agents
JPS62162963A (ja) 1986-01-10 1987-07-18 Sadao Shiosaka 金属コロイド粒子を担体とする低分子物質に対する特異抗体の作成法
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
IN165717B (de) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5217869A (en) 1987-10-13 1993-06-08 Terrapin Technologies, Inc. Method to produce immunodiagnostic reagents
US4963263A (en) 1988-03-24 1990-10-16 Terrapin Technologies, Inc. Method of identity analyte-binding peptides
US5133866A (en) 1988-03-24 1992-07-28 Terrapin Technologies, Inc. Method to identify analyte-bending ligands
US5340474A (en) 1988-03-24 1994-08-23 Terrapin Technologies, Inc. Panels of analyte-binding ligands
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US4923949A (en) 1988-08-03 1990-05-08 Kanegafuchi Chemical Industry Co., Ltd. Ethynylene-disilanylene copolymers and method of preparing same
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5075216A (en) 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5049656A (en) 1988-12-21 1991-09-17 Board Of Regents Of The University Of Nebraska Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques
CA2425745C (en) 1989-03-21 2005-03-29 Philip L. Felgner Expression of exogenous polynucleotide sequences in a vertebrate
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5252743A (en) 1989-11-13 1993-10-12 Affymax Technologies N.V. Spatially-addressable immobilization of anti-ligands on surfaces
US5366862A (en) 1990-02-14 1994-11-22 Receptor Laboratories, Inc. Method for generating and screening useful peptides
CA2039517C (en) 1990-04-03 2006-11-07 David Segev Dna probe signal amplification
US5430138A (en) 1990-07-27 1995-07-04 Chiron Corporation Hydroxyl-protecting groups attached to cytidine nucleotide compounds which are orthogonally removable
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5352775A (en) 1991-01-16 1994-10-04 The Johns Hopkins Univ. APC gene and nucleic acid probes derived therefrom
CA2104449A1 (en) 1991-02-21 1992-08-22 Randall Keith Johnson Treatment of esophageal cancer
US5330892A (en) 1991-03-13 1994-07-19 The Johns Hopkins University MCC gene (mutated in colorectal cancer) used for diagnosis of cancer in humans
AU662906B2 (en) 1991-06-26 1995-09-21 F. Hoffmann-La Roche Ag Methods for detection of carcinoma metastases by nucleic acid amplification
US5140102A (en) * 1991-09-23 1992-08-18 Monsanto Company Pentadecapeptide, guanylin, which stimulates intestinal guanylate cyclase
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
US5969097A (en) * 1992-06-23 1999-10-19 G. D. Searle & Co. Human guanylin
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US5420328A (en) 1992-09-11 1995-05-30 Affymax Technologies, N.V. Methods for the synthesis of phosphonate esters
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5324483B1 (en) 1992-10-08 1996-09-24 Warner Lambert Co Apparatus for multiple simultaneous synthesis
US5397639A (en) 1992-11-25 1995-03-14 Tollini; Dennis R. Securing tape
US5595739A (en) 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
US5601990A (en) * 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
EP0734264B1 (de) 1993-10-26 2004-02-18 Thomas Jefferson University Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung
US5962220A (en) 1993-10-26 1999-10-05 Thomas Jefferson University Compositions that specifically bind to colorectal cells and methods of using the same
US7097839B1 (en) * 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5518888A (en) * 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5489670A (en) * 1993-10-29 1996-02-06 G. D. Searle & Co. Human uroguanylin
US5885574A (en) * 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5597909A (en) * 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5858011A (en) 1995-08-02 1999-01-12 The Procter & Gamble Company Disposable absorbent article having a resilient member
CA2251186A1 (en) * 1996-04-05 1997-10-16 The Johns Hopkins University A method of enriching rare cells
KR100262838B1 (ko) * 1996-04-16 2003-03-15 기시모토 다다미쓰 고형암세포및조직이형성의검출방법,및골수이식및말초혈간세포이식용조직의검사방법
ATE245163T1 (de) 1996-05-03 2003-08-15 Univ Jefferson Impfstoff gegen metastasierenden kolorektalkrebs.
WO1997042506A1 (en) 1996-05-03 1997-11-13 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
US5914238A (en) * 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
AU4003597A (en) * 1996-09-04 1998-03-26 Howard Florey Institute Of Experimental Physiology And Medicine Methods of diagnosing and treating cancer
FI971124A0 (fi) * 1997-03-18 1997-03-18 Locus Genex Oy Metod foer diagnostisering av magcancer
US5874266A (en) * 1997-03-27 1999-02-23 Palsson; Bernhard O. Targeted system for removing tumor cells from cell populations
US6130043A (en) * 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
CA2345000A1 (en) * 1998-10-02 2000-04-13 Diadexus, Inc. A novel method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers
US6960449B2 (en) * 1999-02-10 2005-11-01 Cell Works Diagnostics, Inc. Class characterization of circulating cancer cells isolated from body fluids and methods of use
EP1180157B1 (de) * 1999-05-28 2012-11-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Vacciniavirus-vektor, dem gleichzeitig ein wachstumsfaktor und die thymidinkinase fehlen
CA2404428A1 (en) * 2000-03-27 2001-10-04 Thomas Jefferson University High specificity marker detection
AU2001292728A1 (en) * 2000-09-18 2002-03-26 Thomas Jefferson University Compositions and methods for identifying and targeting stomach and esophageal cancer cells
US6652378B2 (en) 2001-06-01 2003-11-25 Igt Gaming machines and systems offering simultaneous play of multiple games and methods of gaming
CN1679051A (zh) * 2002-08-30 2005-10-05 皇家飞利浦电子股份有限公司 嵌入用于媒体内容识别的指纹数据
US8206704B2 (en) * 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
ES2451496T3 (es) * 2004-06-25 2014-03-27 Thomas Jefferson University Ligandos de guanilato ciclasa C
DE102005041131B4 (de) 2005-08-30 2008-01-31 Phoenix Contact Gmbh & Co. Kg Übertrager
US9001515B2 (en) 2012-04-20 2015-04-07 Cisco Technology, Inc. Universal pull tab release for modules including fiber optic and cable accessibilities
US9707467B2 (en) 2013-10-18 2017-07-18 Under Armour, Inc. Athletic glove
US9707565B2 (en) 2014-04-09 2017-07-18 II Lyman Burdette Lyne Screen assembly for shredding machine

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050208045A1 (en) * 2003-09-15 2005-09-22 Wylie Vale Cripto antagonism of activin and TGF-b signaling
WO2005028433A3 (en) * 2003-09-15 2006-01-05 Res Dev Foundation CRIPTO ANTAGONISM OF ACTIVIN AND TGF-β SIGNALING
AU2004274433B2 (en) * 2003-09-15 2010-08-12 Research Development Foundation Cripto antagonism of activin and TGF-beta signaling
US7820620B2 (en) 2003-09-15 2010-10-26 Research Development Foundation Cripto antagonism of activin and TGF-b signaling
US20110009319A1 (en) * 2003-09-15 2011-01-13 Research Development Foundation Cripto antagonism of activin and tgf-b signaling
US9546210B2 (en) 2003-09-15 2017-01-17 Research Development Foundation Cripto antagonism of activin and TGF-b signaling
EP3444333A1 (de) 2009-10-22 2019-02-20 Thomas Jefferson University Zellbasierte antikrebszusammensetzungen sowie verfahren zur herstellung und verwendung davon
US20120226189A1 (en) * 2009-11-13 2012-09-06 Medical Research Council Cell sampling device
US10327742B2 (en) * 2009-11-13 2019-06-25 United Kingdom Research And Innovation Cell sampling device

Also Published As

Publication number Publication date
US20050196793A1 (en) 2005-09-08
ES2548381T3 (es) 2015-10-16
US7745114B2 (en) 2010-06-29
US7854933B2 (en) 2010-12-21
US20010029020A1 (en) 2001-10-11
EP3388534A1 (de) 2018-10-17
EP2230320A1 (de) 2010-09-22
US20010029019A1 (en) 2001-10-11
CA2404431A1 (en) 2001-10-04
US20010039017A1 (en) 2001-11-08
CA2404428A1 (en) 2001-10-04
ES2346637T3 (es) 2010-10-19
US7785817B2 (en) 2010-08-31
EP1268854A1 (de) 2003-01-02
EP1272665B1 (de) 2010-05-26
JP5122713B2 (ja) 2013-01-16
US20120321552A1 (en) 2012-12-20
US20100015167A1 (en) 2010-01-21
US20050059008A1 (en) 2005-03-17
US6844153B2 (en) 2005-01-18
CA2404432A1 (en) 2001-10-04
DE60140865D1 (de) 2010-02-04
US20010039016A1 (en) 2001-11-08
US20080241064A1 (en) 2008-10-02
US8946168B2 (en) 2015-02-03
EP1272665A1 (de) 2003-01-08
US20050164267A1 (en) 2005-07-28
ATE469242T1 (de) 2010-06-15
US7485422B2 (en) 2009-02-03
CA2404431C (en) 2011-06-07
JP2003535580A (ja) 2003-12-02
US20110104050A1 (en) 2011-05-05
EP1272665A4 (de) 2005-01-12
EP1268854A4 (de) 2003-05-02
EP1274861A4 (de) 2005-09-28
US20020012931A1 (en) 2002-01-31
EP2230320B1 (de) 2015-07-01
WO2001073133A1 (en) 2001-10-04
WO2001073132A1 (en) 2001-10-04
US7479376B2 (en) 2009-01-20
JP2003528628A (ja) 2003-09-30
US9429576B2 (en) 2016-08-30
US20110086064A1 (en) 2011-04-14
JP2003532389A (ja) 2003-11-05
US20170049869A1 (en) 2017-02-23
EP2949762B1 (de) 2018-05-09
US20150104382A1 (en) 2015-04-16
ATE452989T1 (de) 2010-01-15
US20040033520A1 (en) 2004-02-19
WO2001073131A1 (en) 2001-10-04
US8067007B2 (en) 2011-11-29
AU2001249504A1 (en) 2001-10-08
PT1272665E (pt) 2010-08-31
US6767704B2 (en) 2004-07-27
US20040224355A1 (en) 2004-11-11
AU2001249503A1 (en) 2001-10-08
US20090215089A1 (en) 2009-08-27
AU2001249548A1 (en) 2001-10-08
EP1274861B1 (de) 2009-12-23
WO2001073133A9 (en) 2003-06-12
EP2949762A1 (de) 2015-12-02
DE60142228D1 (de) 2010-07-08
US20110250228A1 (en) 2011-10-13
EP1274861A1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
US9429576B2 (en) Compositions and methods for identifying and targeting cancer cells of alimentary canal origin
US7829276B2 (en) Methods of using CRCA-1 as a stomach and esophageal cancer marker
CA2299630C (en) Compositions that specifically bind to colorectal cancer cells and methods of using the same
US7316902B2 (en) Compositions that specifically bind to colorectal cancer cells and methods of using the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: THOMAS JEFFERSON UNIVERSITY, PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WALDMAN, SCOTT A.;PARK, JASON;SCHULZ, STEPHANIE;REEL/FRAME:011897/0242

Effective date: 20010523

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION